AbbVie’s Elahere gains approval in Canada for ovarian cancer
vzphotos/iStock Editorial via Getty Images Health Canada has approved AbbVie's (NYSE:ABBV) antibody-drug conjugate Elahere (mirvetuximab soravtansine) for ovarian cancer. The treatment is approved for women who have received one to…
Share